Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants (NCT04987333), a non-randomized phase 1 study. The primary outcome is Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa.

2. Clinical Question

3. Trial Design

This was a Phase 1, open-label, non-randomized, sequential-group, single-dose study of efavaleukin alfa in healthy Chinese, Japanese, and Caucasian participants. The registry record gives the study status as completed and enrollment as 32. Participants received a single subcutaneous dose, with Chinese participants assigned to either dose level 1 or dose level 2, and Japanese and Caucasian participants assigned to dose level 2. The actual dose amounts are not reported in the registry record.

Each of the four groups had 8 participants at risk in the posted adverse-event data. Because the groups were sequential and not randomized, they should not be treated as equivalent arms in a controlled treatment comparison. The study does not describe a placebo or untreated group. Differences between groups could reflect population characteristics, dose level, study sequence, or other factors; the record does not report an analysis that separates these influences.

The primary objective concerned pharmacokinetics after a single administration. Blood samples were scheduled from pre-dose through Day 43, with multiple post-dose collections. Safety and immunogenicity were also assessed: secondary outcomes included treatment-emergent adverse events and anti-efavaleukin alfa and anti-interleukin 2 antibodies. Details of the methods used for those assessments are not reported in the registry record.

The registry record lists study start as 2021-08-09 and primary completion as 2022-10-03. It does not report the rationale for the enrollment target, the detailed protocol, or the order and timing of enrollment within the sequential groups. The record reports no statistical analyses for the outcomes.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Pharmacokinetic (PK) population: all participants who received at least 1 dose of efavaleukin alfa and had evaluable PK data.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Safety population: all participants who received at least 1 dose of efavaleukin alfa and had at least 1 postdose safety assessment.

6. Primary Endpoint

The registry lists the primary outcome as Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa, measured over Day 1: Pre-dose, 6, 12, & 16 hours post-dose, and days 2 (24 hours post-dose), 3, 4, 5, 6, 8, 11, 15, 22, 29 and 43.

The primary endpoint was maximum observed serum concentration of efavaleukin alfa, abbreviated Cmax, with units of ng/mL. Cmax is the highest measured serum concentration among the scheduled samples after a dose. It is a pharmacokinetic measure: it describes the observed peak concentration, not a clinical response or a direct measure of benefit.

The registry record identifies the reported summary as a geometric mean with geometric coefficient of variation. In general, a geometric mean summarizes concentration data on a multiplicative scale, while a geometric coefficient of variation describes relative spread around that summary. These are useful ways to characterize pharmacokinetic measurements, which can vary proportionally rather than by a constant absolute amount. That general explanation does not establish how the study handled its data beyond the summary types named in the record.

Blood sampling was scheduled on Day 1 before dosing and at 6, 12, and 16 hours post-dose, then on days 2, 3, 4, 5, 6, 8, 11, 15, 22, 29 and 43. The endpoint therefore depends on the concentration measurements captured at those scheduled times. The record does not report participant-level measurements, group Cmax estimates, variability values, confidence intervals, or comparisons. It also does not state how missing or unevaluable samples affected Cmax calculations.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record describes a single-dose pharmacokinetic study, not a randomized efficacy trial. Its stated primary objective was to evaluate pharmacokinetics after subcutaneous administration. The primary measure, Cmax, is the maximum observed serum concentration. The record names the geometric mean and geometric coefficient of variation as the summary format, but it does not report numerical estimates or an inferential analysis.

What does Cmax represent?

In general, Cmax is the highest measured concentration among the samples collected after dosing. It is a descriptive pharmacokinetic endpoint. Its value depends on the timing of sample collection and the concentrations measured at those times. It should not be read as a clinical outcome or as proof of a treatment effect. The listed schedule begins with a pre-dose sample on Day 1, includes post-dose measurements on Day 1 and days 2 through 43, and supplies the sampling framework named in the record. The record does not describe the laboratory assay, sample handling, or procedures for values below assay limits.

Why report a geometric mean?

In general, concentration data often have a multiplicative pattern of variation: values may differ in relative rather than fixed absolute amounts. A geometric mean summarizes such data by working on a logarithmic scale and returning the summary to the original scale. A geometric coefficient of variation expresses relative dispersion around that geometric summary. These measures can make a set of pharmacokinetic observations easier to characterize when values are skewed. This is general statistical context; the registry record does not report the distribution of the study data or confirm whether other summaries were also calculated.

What does the study structure allow?

Allocation was non-randomized, masking was none, and the model was sequential. In general, non-randomized groups can differ in ways other than the feature being compared. Here, the groups also differ by population and, for the Chinese participants, dose level. Sequential enrollment can make interpretation more dependent on the study’s conduct and timing. The record does not report a randomized comparator, a masking procedure, or an adjustment strategy that would support causal comparisons across the groups. Accordingly, group descriptions are best understood as separate study cohorts rather than randomized treatment arms.

What can uncertainty statistics tell a reader?

In general, an estimate describes the data observed, while a confidence interval communicates uncertainty around that estimate under the specified analysis assumptions. A narrow interval indicates greater precision than a wide interval, but neither interval alone establishes clinical importance. A hypothesis test and its p-value address compatibility between data and a stated null model, subject to the analysis assumptions; a p-value does not measure effect size. The registry record does not report confidence intervals, p-values, test statistics, or a statistical analysis plan. There is therefore no basis to describe the precision or statistical significance of Cmax group differences.

How should sample-size illustrations be understood?

General sample-size planning asks how much information a future design may need to detect a specified effect under stated assumptions. The planning illustration described for the posted material uses a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and effects defined as stated fractions of an observed effect. It is an illustration based on an observed effect, not the study’s own design justification and not observed power. The registry record does not report a protocol sample-size justification, and the non-randomized sequential cohorts are not a like-for-like two-arm comparison. No numerical planning estimates or effect values are reported in the registry record.

For over-dispersed count data, a general statistical concern is that the variance can exceed what a simple Poisson model assumes; accounting for that extra variation may be important when such outcomes are analyzed. The registry record does not identify a count-data model or report an analysis of this kind. More broadly, no analysis methods are posted for the six outcome measures. Any model choice, transformation, adjustment, or treatment of outliers beyond the named summary statistics is not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry record names a primary pharmacokinetic endpoint and secondary outcomes concerning treatment-emergent adverse events and anti-efavaleukin alfa and anti-interleukin 2 antibodies. It lists 6 outcome measures in total but does not provide an analysis count. No multiplicity procedure is reported in the registry record. In general, multiplicity matters when several outcomes, groups, or comparisons are examined, because the chance of a nominally notable result can depend on how many tests are performed. Without a reported analysis plan or inferential results, it is not possible to determine whether multiplicity was addressed or whether any findings were designated exploratory.

The pharmacokinetic population is defined as participants who received at least 1 dose and had evaluable pharmacokinetic data. The number of participants meeting that definition is not reported in the registry record. The record does not specify how many participants contributed to each endpoint, how missing samples were handled, or how unevaluable pharmacokinetic data were treated. It also does not report missing-data patterns or sensitivity analyses. Therefore, the effect of incomplete measurements on the Cmax summaries cannot be assessed.

The secondary outcome names do not give antibody results or detailed safety-analysis methods. The record does not report a statistical analysis plan, interim analyses, or further analysis-population definitions. No assumptions about those procedures can be made from the endpoint listings alone.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: hepatocellular injury (12.5%), hypersensitivity (12.5%).

The posted safety figures are counts of participants, not comparisons of event rates against a control group. In each of the four groups, 8 participants were at risk for the listed safety outcomes. The record reports 1 participant with a serious adverse event in Group 1 and 1 in Group 3, with 0 deaths in every group. It lists 8 participants with one or more other adverse events in each group. These categories should be read as reported; the record does not provide additional event-level detail in the registry entries.

Hepatocellular injury and hypersensitivity are listed as the top serious adverse-event terms, each at 12.5%. The record does not give a group-specific breakdown for those terms or explain whether a participant could contribute to more than one term. These percentages and counts do not establish a comparative risk, especially in a non-randomized study without a control group. They describe the reported safety experience in these small cohorts, not what would occur in another population or under another regimen.

In general, safety interpretation also depends on event definitions, follow-up, exposure, and ascertainment methods. Those details are not reported in the registry record beyond the outcomes and timeframe information available.

12. What the Result Does, and Does Not, Mean

The record describes a Phase 1 study of single-dose efavaleukin alfa in healthy Chinese, Japanese, and Caucasian participants. Its primary question was pharmacokinetic: what maximum serum concentration was observed after administration? The endpoint and sampling schedule are specified, but the Cmax results are not reported in the registry record. Thus, the posted record does not support a numerical statement about peak concentrations, their variability, or differences across groups.

The study also reports participant counts for adverse events. Those figures describe what was recorded in the four cohorts; they do not show how safety compares with no treatment or another treatment. The sequential, non-randomized design is not a like-for-like controlled comparison, and the record does not report an adjusted analysis. The antibody outcomes are named, but their results are not reported in the registry record.

In general, a pharmacokinetic measure can characterize drug concentration over time, while safety counts can describe reported adverse events. Neither type of information alone establishes clinical benefit. This study’s population is described as healthy participants, so the registry record does not directly characterize outcomes in people with inflammatory diseases. The condition field lists inflammatory diseases, but the participants are described as healthy and the study objective is pharmacokinetic.

The record does not report confidence intervals, p-values, a detailed analysis plan, or a sample-size justification. As a result, the precision of estimates and the rationale for the enrollment target cannot be assessed. The study should be understood in the registry record it posts: its design, intended measurements, and limited safety counts, rather than as evidence of a controlled treatment comparison or a clinical outcome.

13. Why This Trial Matters Statistically

This study illustrates an important distinction in clinical research: a Phase 1 pharmacokinetic study can be designed to characterize drug concentrations without being a randomized test of clinical benefit. The registry record identifies Cmax as the primary endpoint and describes a detailed post-dose sampling schedule. Those features show the type of information the study sought, even though numerical Cmax results are not reported in the registry record.

Its group structure also demonstrates why comparison requires attention to design. The cohorts were sequential and non-randomized, and they differed by population and dose assignment. A direct contrast across groups would therefore require cautious interpretation; the record does not report a model or adjustment that resolves such differences. Recording group labels alone does not make groups exchangeable.

The safety figures are another useful statistical example. Counts can be informative about what was observed in a study, but the absence of a control group limits comparative interpretation. A listed serious event count is not an estimate of excess risk attributable to the intervention. Likewise, a percentage attached to an event term needs context about its denominator and group distribution, which the record does not give for the listed top terms.

Finally, the record distinguishes outcome definitions from outcome results. It names pharmacokinetic and antibody measures, yet does not post their estimates or analyses. For statistical readers, that difference matters: an endpoint description tells what was intended to be measured, while results and uncertainty estimates are needed to evaluate observed patterns and their precision.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpreting this study from the registry record is that it does not report the primary Cmax results. No group estimates, measures of variability, confidence intervals, or comparative analyses are available in the record. Although the endpoint summary type and sampling schedule are described, the observed pharmacokinetic findings cannot be assessed.

The study was non-randomized, unmasked, and sequential, with no control group described. Its cohorts varied by population and dose assignment, so differences between them would not isolate a single source of variation. The actual dose amounts are not reported in the registry record. The record also does not report how enrollment sequence, baseline characteristics, or other potential differences were handled analytically.

The record defines a pharmacokinetic population but does not report the number included in it. Handling of missing samples, assay limits, protocol deviations, and unevaluable measurements is not reported in the registry record. The antibody outcome results are also absent. Safety counts are available, but details of event onset, duration, severity beyond serious classification, and group-specific serious-event terms are not reported in the registry record.

There is no posted statistical analysis plan, sample-size justification, interim-analysis information, or inferential analysis. Consequently, the record does not permit evaluation of multiplicity, model assumptions, or precision. Finally, the participants are described as healthy, which limits how directly the results, if available, could be applied to people with inflammatory diseases.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants — NCT04987333.
• Registry record last updated 2024-03-29; status last verified 2023-10.
• Results first posted 2024-03-29.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The completed Phase 1 study enrolled 32 healthy Chinese, Japanese, and Caucasian participants. It was open-label, non-randomized, sequential, and evaluated a single subcutaneous dose of efavaleukin alfa at two dose levels. The primary endpoint was maximum observed serum concentration, summarized as a geometric mean with geometric coefficient of variation, with blood sampling scheduled through day 43.

The registry record reports no statistical analyses and does not report Cmax results, antibody results, or confidence intervals. Safety figures list 8 participants at risk in each group, serious adverse events in 1 participant in Group 1 and 1 in Group 3, and 0 deaths in each group. The design does not provide a randomized control comparison.